Why Revelation Biosciences (REVB) Stock Is Down 38%
Why Revelation Biosciences (REVB) Stock Is Down 38%
Revelation Biosciences Inc (NASDAQ:REVB) shares are trading lower by 38% to 58 cents during Tuesday's session after the company said it entered a definitive agreement for the immediate exercise of outstanding warrants to purchase 4,064,040 shares of common stock at $1.00 per share.
啓示生物科學公司（納斯達克：REVB）在週二的交易中股價下跌38%，至58美分，此前該公司表示已達成一項關於立即行使未行使warrants的正式協議，以購買4,064,040股普通股，價格爲每股1.00美元。
The shares, registered under a Form S-3 filing, are expected to generate approximately $4 million in proceeds. The transaction is set to close on December 3, pending customary conditions.
這些股份在S-3表格備案中註冊，預計將產生約400萬美元的收益。此次交易預計將在12月3日完成，待符合慣例條件。
Roth Capital Partners is serving as the financial advisor for the deal. REVB shares otherwise gained Monday after the company announced FDA acceptance of Gemini IND.
羅斯資本夥伴公司擔任該交易的財務顧問。除此外，REVb股票在週一上漲，此前該公司宣佈FDA接受了Gemini IND。
Read Also: South Korean ETFs Slide On President's Emergency Martial Law Declaration: 'Protect The Constitutional Democratic Order'
另請閱讀：韓國etf在總統實施緊急戒嚴令時下滑：'保護憲法民主秩序'
According to data from Benzinga Pro, REVB has a 52-week high of $25.26 and a 52-week low of $0.51.
根據Benzinga Pro的數據，REVb的52周高點爲25.26美元，52周低點爲0.51美元。
譯文內容由第三人軟體翻譯。
